Dr. Mary Claire Haver's Women's HRT: How a Regular Patient Gets Access

Who Is Dr. Mary Claire Haver and Why Does Her HRT Stance Matter?

Dr. Mary Claire Haver is a board-certified OB-GYN based in Texas whose social media presence, podcast appearances, and 2024 book "The New Menopause" have made her one of the most influential voices in women's midlife health. She does not speak as a distant academic. She speaks as a patient.

Her Public Disclosure

In multiple interviews, including a widely-shared conversation on the "Diary of a CEO" podcast and posts to her Instagram audience of more than four million followers, Dr. Haver has stated plainly that she uses HRT herself. Her reported regimen includes a transdermal estradiol patch and oral micronized progesterone (brand name Prometrium in the US). She has described starting HRT during her own perimenopause and experiencing significant symptom relief, including improved sleep, reduced brain fog, and stabilized mood.

This public disclosure matters clinically because it shifts the conversation from theoretical to lived. A physician who prescribes and personally uses the therapy she recommends occupies a different rhetorical position than one who has only read the literature. Her credibility with patients stems from that combination.

Her Clinical Background

Dr. Haver completed her OB-GYN residency at Louisiana State University and later trained specifically in menopause medicine. She developed the Galveston Diet, a nutrition program aimed at midlife women, before pivoting to broader menopause education through The Pause Life platform. She holds no financial relationship with any single pharmaceutical manufacturer of hormone products, which she has disclosed publicly. That matters when evaluating whether her recommendations reflect clinical evidence or commercial interest.

What Exactly Does Dr. Haver Take? The Clinical Details

Transdermal Estradiol

Dr. Haver has confirmed she uses a transdermal estradiol patch rather than oral estrogen. This distinction is clinically significant, not cosmetic. Oral estrogen undergoes first-pass hepatic metabolism, which raises sex hormone-binding globulin, triglycerides, and coagulation factors to a degree that transdermal delivery avoids. A large French cohort study (E3N, N=80,377) found that transdermal estradiol did not increase venous thromboembolism risk, while oral estrogen was associated with a relative risk of approximately 1.7 compared with non-use [1].

Common transdermal estradiol products available in the United States include:

• Patch formulations: Climara (weekly), Vivelle-Dot (twice weekly), and generic estradiol patch (twice weekly)
• Gel formulations: EstroGel 0.06%, Divigel
• Spray: Evamist

Generic twice-weekly patches typically cost $20-$50 per month at major pharmacy chains without insurance.

Micronized Progesterone

For women with a uterus, estrogen must be paired with a progestogen to prevent endometrial hyperplasia. Dr. Haver has specifically recommended body-identical micronized progesterone (Prometrium, 200 mg taken orally at bedtime for 12 days per cycle in sequential regimens, or 100 mg nightly in continuous regimens) rather than synthetic progestins such as medroxyprogesterone acetate (MPA).

This preference aligns with data. The WHI trial, which used conjugated equine estrogen plus MPA, showed a modest increase in breast cancer risk [2]. A re-analysis of French E3N data found no increased breast cancer risk with estradiol plus micronized progesterone over five years of use [3]. The Menopause Society's 2023 Position Statement acknowledges this distinction and states that micronized progesterone may have a more favorable safety profile than synthetic progestins for breast tissue [4].

Testosterone

Dr. Haver has also spoken publicly about the role of testosterone in women's health, including libido, energy, and cognitive function. She has mentioned using compounded testosterone, though she is careful to note it is prescribed off-label in the US because the FDA has not approved a testosterone product specifically for women. Compounded low-dose testosterone creams or pellets are available through licensed compounding pharmacies with a valid prescription.

The Clinical Case for Women's HRT: What the Evidence Shows

Symptom Relief

Vasomotor symptoms (hot flashes, night sweats) affect approximately 75% of women during perimenopause and early postmenopause, according to the North American Menopause Society [4]. Estrogen therapy is the most effective treatment available. A Cochrane review of 24 randomized controlled trials (N=3,329) found that oral and transdermal estrogen reduced hot flash frequency by approximately 75% compared with placebo [5].

That number deserves emphasis. A 75% reduction is not marginal relief. It is the difference between waking four times a night and sleeping through.

Bone and Cardiovascular Considerations

The Women's Health Initiative (WHI) initially alarmed clinicians and patients when its 2002 results were published. But the alarm was partly a misreading of the data. The WHI enrolled women at a mean age of 63, well past the 10-year window of menopause onset. When Manson and colleagues re-analyzed WHI data stratified by age at initiation, women aged 50-59 who started estrogen-alone therapy showed a 28% lower all-cause mortality compared with placebo at 18-year follow-up [6].

The NAMS 2023 Position Statement summarizes this as the "timing hypothesis": HRT started within 10 years of menopause onset, or before age 60, carries a favorable cardiovascular risk-benefit ratio for most healthy women [4].

For bone health, estrogen therapy reduces fracture risk. The WHI showed a 34% reduction in hip fracture risk in the combined estrogen-progestin arm [2].

Cognitive Function

This area carries more uncertainty. Observational data suggest that women who use estrogen therapy during perimenopause may have lower rates of Alzheimer's disease later in life, but randomized trial data in older women have not confirmed a protective effect. Dr. Haver discusses this distinction publicly, framing brain health as a compelling reason to start HRT early rather than waiting until symptoms become severe. The ELITE trial (N=643) found that estradiol reduced subclinical atherosclerosis progression (measured by carotid intima-media thickness) only in women who started within six years of menopause, not in those who started 10 or more years later [7].

Who Qualifies for HRT? The Clinical Screening Checklist

Most healthy women in perimenopause or early postmenopause qualify for HRT consideration. Absolute contraindications are narrow. They include:

• Active or recent estrogen-receptor-positive breast cancer
• Active deep vein thrombosis or pulmonary embolism (untreated)
• Active arterial thromboembolic disease (recent stroke or MI)
• Undiagnosed vaginal bleeding
• Known or suspected pregnancy

Women with a personal history of VTE may still be candidates for transdermal estradiol, since transdermal delivery does not increase VTE risk in the same way oral estrogen does. This is an individualized risk-benefit conversation, not an automatic exclusion.

The NAMS 2023 statement states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [4]

How a Regular Patient Gets Access: Four Practical Pathways

This is the question most of Dr. Haver's followers are actually asking. She can describe her regimen in detail, but the next step requires a licensed clinician who can prescribe. Here are the four pathways, ordered from lowest to highest friction.

Pathway 1: Telehealth Menopause Platforms

Telehealth platforms that specialize in menopause care have compressed the access gap significantly. A woman in most US states can complete an intake questionnaire, have a video visit with a licensed NP or MD, and receive a prescription within 24-72 hours. Platforms operating in this space include HealthRX, Midi Health, Alloy Women's Health, and Evernow.

What to expect:

• Intake form covering symptom severity, personal and family medical history, current medications
• Video or async consultation (15-30 minutes)
• Lab review (FSH, estradiol, TSH, and sometimes a lipid panel, though labs are not required to diagnose menopause clinically)
• Prescription sent to a local pharmacy or mail-order pharmacy

Cost: $99-$199 for the initial consultation on most platforms, plus $30-$120/month for generic HRT products.

Pathway 2: Menopause Society Certified Practitioners

The North American Menopause Society (now The Menopause Society) maintains a directory of Nationally Certified Menopause Practitioners (NCMPs) at menopause.org. These are physicians, NPs, and PAs who have passed a menopause-specific certification exam. The directory is searchable by zip code.

This pathway is the gold standard for complex cases, including women with prior hormone-sensitive cancers who need nuanced counseling, women with multiple cardiovascular risk factors, or women seeking compounded testosterone alongside estrogen.

Pathway 3: Primary-Care or OB-GYN Visit

Many women already have a relationship with a primary-care physician or OB-GYN. The barrier is not always willingness. It is often time and training. A 2019 survey published in Menopause found that 70% of OB-GYN residents reported receiving less than four hours of menopause education during their training [8].

The practical workaround: bring a printed copy of the NAMS 2023 Position Statement to the appointment. Ask specifically whether you qualify for a trial of transdermal estradiol plus micronized progesterone. Frame the conversation around symptom severity and functional impairment (sleep loss, inability to concentrate, relationship strain from mood changes) rather than asking generally about "hormones."

If a provider declines without clinical justification, requesting a referral to a menopause specialist is entirely reasonable.

Pathway 4: Compounding Pharmacies for Testosterone

FDA-approved testosterone products for women do not exist in the US as of early 2025. Women who want testosterone therapy, whether for libido, energy, or other indications, require a prescription for a compounded product. This requires a prescriber willing to write an off-label order and a licensed 503A compounding pharmacy.

Dr. Haver has noted publicly that she works with a compounding pharmacy for her testosterone. Typical compounded testosterone for women involves a 1-2% cream applied to the inner arm or thigh, dosed at 0.5-2 mg per day. Lab monitoring of total testosterone levels every three to six months is standard practice to avoid supraphysiologic levels.

What Labs Should Be Ordered Before Starting HRT?

The Minimal Panel

The NAMS 2023 guidelines do not require lab testing to diagnose menopause or to initiate HRT in women aged 45 or older with classic vasomotor symptoms. However, most clinicians order a baseline panel for safety and follow-up purposes:

• FSH and estradiol (to confirm menopausal transition if age or symptoms are ambiguous)
• TSH (thyroid dysfunction mimics many menopause symptoms)
• Lipid panel (cardiovascular risk assessment)
• Fasting glucose or HbA1c (metabolic baseline)
• Mammogram (current, within 12 months)
• Blood pressure measurement

Follow-Up Monitoring

After initiating HRT, a follow-up visit at 6-12 weeks allows assessment of symptom response, side effects (bloating, breast tenderness, spotting), and dose adjustment. Ongoing annual monitoring includes mammography, blood pressure, and subjective symptom review.

Dose Titration: Starting Low and Adjusting

Most clinicians start at a low estradiol dose and titrate based on symptom control.

Common starting doses for transdermal estradiol:

• Patch: 0.025 mg/day or 0.0375 mg/day (lowest available strengths)
• Gel: 0.5 g/day of EstroGel (delivers approximately 0.35 mg estradiol)

If symptoms persist at four to six weeks, the dose is increased to 0.05 mg/day patch or 1 g/day gel. Women with severe symptoms may require 0.1 mg/day.

Micronized progesterone is dosed at 200 mg orally for 12 days per month (sequential) or 100 mg nightly (continuous). Sequential regimens may produce a monthly withdrawal bleed, which some perimenopausal women prefer for confirming cycle status. Continuous regimens are more common in women who are clearly postmenopausal and prefer no bleeding.

Why Dr. Haver's Advocacy Has Changed Practice

Before voices like Dr. Haver's reached mainstream audiences, the Women's Health Initiative's 2002 publication had created a near-decade-long clinical retreat from HRT. Prescriptions fell by more than 50% between 2002 and 2004, according to IMS Health data cited in a 2007 Obstetrics and Gynecology review [9]. Women who might have benefited from therapy went untreated. Some turned to unregulated supplements with no randomized trial evidence.

Dr. Haver and clinician-educators like Dr. Avrum Bluming (co-author of "Estrogen Matters") began correcting the record publicly. Her position aligns with the formal reassessment articulated by the Endocrine Society, NAMS, and the British Menopause Society, all of which have issued updated guidance affirming HRT's safety and efficacy for symptomatic women under 60 with no contraindications.

The British Menopause Society's 2020 consensus statement puts it directly: "There is no justification for any arbitrary limit on the duration of use of HRT. The decision to use HRT and for how long should be made by each woman in consultation with her clinician." [10]

Specific Cost Estimates for the Most Common HRT Regimen

Cost is a real barrier. Here is what the most common evidence-based regimen costs at US pharmacies as of early 2025, using GoodRx pricing for generic products:

| Product | Dose | Approx. Monthly Cost (GoodRx) | |---|---|---| | Generic estradiol patch (twice-weekly) | 0.05 mg/day | $25-$45 | | Generic micronized progesterone | 100 mg nightly | $30-$60 | | Generic estradiol gel (EstroGel generic) | 0.5 g/day | $40-$80 | | Compounded testosterone cream 1% | 0.5 mg/day | $50-$90 |

Total for the estradiol patch plus progesterone regimen: approximately $55-$105 per month without insurance. With most commercial insurance plans covering generic hormone products, out-of-pocket cost drops to $5-$20 per month at the copay level.